Synexus Recruits 37% of Patients at 7 Sites for Global Hypertension Study
MANCHESTER, England--(Business Wire)-- Synexus, based in Manchester, UK, has once again recruited the highest number of patients for a major global study. Following fast from its recent JUPITER success, Synexus has this time, recruited 1221 patients at seven UK sites, averaging 174 patients per site for a hypertension study. A total of 3273 patients were recruited worldwide at 87 sites. Professor Neil Poulter, Chair of Preventive Cardiovascular Medicine at Imperial College, London, and in charge of the hypertension study, recognises the benefits of Synexus dedicated trial sites and innovative patient recruitment strategies: "Working with Synexus has made a genuine difference to the cost effectiveness of the overall trial because of the speed with which we were able to recruit into the study. The proactive patient recruitment procedures Synexus use, together with their dedicated teams, streamlined so much of what can often be a laborious and ineffective process." Commenting on Synexus role in this major study, Michael Fort, CEO said: "Following on from our success with JUPITER this demonstrates that our methods consistently deliver excellent results for our clients, including fast and reliable patient recruitment and the resulting cost efficiencies we are able to achieve." - ends - Synexus background Synexus headquartered in Manchester, England, is the world`s largest multi-national company dedicated to the recruitment of clinical trials at its own research centres across the globe on behalf of its pharmaceutical, biotech and CRO clients. Synexus has 16 research centres across the UK, Poland, Hungary, Bulgaria, India and South Africa staffed by full time GCP trained investigators. Synexus currently has more than twelve thousand patients enrolled in clinical trials. Vane Percy & Roberts Simon Vane Percy Office: +44 (0) 1737 821 890/892 Mobile: +44 (0) 7710 005910 Home: +44 (0) 1883 724505 (e) simon@vanepercy.com Copyright Business Wire 2009
© Thomson Reuters 2009 All rights reserved



